Kornimate/medical-research-clean huggingface dataset:
comparison of analgesic requirements in patients receiving nuss operation using 2 different anesthetic adjuvants

Conditions: Chest Wall Disorder

Summary: nowadays, general anaesthesia is carried under "balanced anesthesia technique" in which many anesthetic adjuvants are used simultaneously, including opioid analgesics in order to reduce the amount of inhalation agents. the most popular adjuvants used are remifentanil, which is an opioid analgesic, and dexmedetomidine. both of these agents are short acting, can be infused with targeted concentrations, excreted shortly from the body with stable hemodynamics. remifentanil, when infused for more than 2 hours, causes hyperalgesia to increase the amount of pain postoperatively as well as the amount of opioid analgesics. however, dexmedetomidine does not cause hyperalgesia and is known to have an opioid -sparing effect. in our center. in this study, we aim to compare the effects of remifentanil and dexmedetomidine on postoperative pain in patients undergoing nuss procedure, which is a very painful operation on the chest wall.


Eligibility criteria:
inclusion criteria: 1. adults aged \>20 2. patients undergoing nuss bar operation (pectus excavatum repair surgery) 3. american society of anesthesiologists classification i \~ iii exclusion criteria: 1. drug abuse history 2. chronic pain in need of continuous opioid analgesics administration 3. history of psychiatric diseases 4. preoperative bradycardia (heart rate \< 50/min) or arrythmia 5. cardiac diseases other than diabetes or hypertension - coronary artery disease, ischemic heart disease 6. moderate liver or kidney dysfunction 7. pregnant or breast feeding women 8. hypersensitivity to the study drugs 9. patients who do not agree to participate

Keywords: pectus excavatum
patient satisfaction in treatment of non-complex fractures and dislocations in hospitals vs general practitioners

Conditions: Fractures, Bone; Dislocations

Summary: treatment of fractures and dislocations are generally organized in the hospital setting. however, equal care for patients with non-complex fractures or dislocations may be provided in general practices. while substitution of trauma care from the secondary to the primary care setting is stimulated by the government and insurers, it is unknown what the patient satisfaction level is and which determinants affect this patient satisfaction. therefore, the primary objective of this study is to determine the effect of treatment in a general practice on patient satisfaction compared to treatment in a hospital. the secondary objectives include assessments in quality of life, patient-reported outcomes and cost-effectiveness. besides, results will be discussed using a small focus group consisting of patients (n=15 per group) and healthcare providers.


Eligibility criteria:
inclusion criteria: * x-ray confirmed diagnosis of a non-complex fracture or dislocation, which can be treated in the primary care setting according to the treatment protocol. * ability of the patient or assigned representative to understand the content of the patient information/informed consent form. * signed and dated written informed consent. parents of patients of age 12-17 must provide a signed and dated written informed consent as well. exclusion criteria: * patients of age 11 years and younger. * patients presenting outside ordinary business hours.
motivational interviews with women experiencing sexual dysfunction during menopause period

Conditions: Sexual Dysfunction

Summary: the aim of this study is to evaluate the effect of motivational interviews with women who experience sexual dysfunction during menopause on sexual quality of life and self-efficacy.the population of the study consisted of menopausal women who applied to the gynecology outpatient clinic of kahramanmaraş sütçü i̇mam university health practice and research hospital. it was calculated as 164 women (82 experimental, 82 control).in data collection, 'personal information form (ek- )', 'arizona sexual experiences scale (acyö) (ek- )', 'sexual quality of life scale-female (siqq-f) (ek-)' and 'sexual self-efficacy scale' (annex- )' was used.

aim: this study was conducted to determine the effect of motivational interviewing on sexual quality of life and sexual self-efficacy in menopausal women with sexual dysfunction. methods: this randomized controlled study was conducted with 164 menopausal women with sexual dysfunction who applied to the gynecology outpatient clinic of a university hospital in southern turkey (82 experimental, 82 control). the data were collected using a personal information form, the arizona sexual experiences scale - female version questionnaire (asex-f), the sexual quality of life-female questionnaire (sqol-f) and the sexual self-efficacy scale (sses). menopausal women with sexual dysfunction (with a score of 19 and above on the asex-f) who applied to the gynecology outpatient clinic of the relevant hospital were invited to the study. before starting the motivational interviews with menopausal women in the experimental group; the pif, the sqol-f and the sses were applied and their pre-test data were obtained. after the pre-test data were obtained, 4 sessions of motivational interviews were conducted with the women, 1 session per week for four weeks. motivational interviews were completed with face-to-face interviews lasting 20-30 minutes for each woman, and those in the control group did not receive any intervention.

Eligibility criteria:
inclusion criteria: * being able to read and write, * ability to communicate * being sexually active, * having entered menopause in the last 3 years, * having entered menopause naturally, * diagnosis of sexual dysfunction according to the arizona sexual experiences scale (total score ≥19). exclusion criteria: * having any diagnosed psychiatric illness, * having entered menopause surgically, * being on hormone replacement therapy

Keywords: menopause period motivational interview sexual dysfunction sexual quality of life midwifery
neuropeptide therapy of recent onset type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: this study evaluates the delivery of substance p via the celiac artery in the treatment of recent onset type 1 diabetes.


Eligibility criteria:
inclusion criteria: * recent onset t1d (cda 2013 guidelines: see link in links section * age 10-18 years * disease duration 3-30 months * fasting c-peptide (measured at screening) greater than or equal to 33 pmol/l * post honeymoon phase based on the following criteria: history of hba1c values and insulin requirements from diagnosis indicating a honeymoon period followed by increased insulin requirements which at time of recruitment are \> 0.50 units/kg together with an hba1c value \> 7.2 %; patients with diabetes duration \> 3 months who never experienced a honeymoon period as reflected by consistent hba1c values \> 7.2 % from the time of diagnosis and at the time of recruitment are using an insulin dose \> 0.50 units/kg. * the presence of one or more of the trpv1 alleles similar to those found in patients currently enrolled in the trpv1-north american - european study. * stimulated c-peptide (measured at mixed meal tolerance at stage a and stage b of sp trial) ≥ 200 pmol/l and less than or equal to 1500 pmol/l. exclusion criteria: * patients with known co-morbidities, including ace-inhibitor treated hypertension as well as chromosomal abnormalities, involving one or more organ systems. * type 2 diabetes mellitus * patients with a known radiographic contrast allergy * pregnancy.

Keywords: neuropeptide therapy onset
image-guided gynecologic brachytherapy

Conditions: Cervical Cancer; Uterine Cancer; Vaginal Cancer; Carcinoma of the Vulva

Summary: standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. the treatment being studied consists of standard brachytherapy with the additional use of mri to guide the insertion of radioactive applicators. the purpose of the study is to find out whether mri-guided brachytherapy is practical and beneficial when compared to the standard ct-guided brachytherapy placement. the investigators are hoping that this mri procedure will decrease the risk of giving too high a radiation dose to the bladder or bowel.

the insertion of the brachytherapy applicator will be administered in the advanced multimodality image-guided operating (amigo) suite at brigham and women's hospital. subjects will undergo an mri scan in the amigo suite ensuring proper placement of the applicator. subjects may have an optional fmiso-pet scan. subjects will have a follow-up visit including physical exam, pap smear, and mri of the pelvis and/or pet scan 90 days after treatment. subjects will have a follow-up visit including physical exam, pap smear, and mri of the pelvis and/or pet scan 180 days after treatment.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed carcinoma of the cervix (stage i-iva), carcinoma of the uterus (stage iiib), carcinoma of the vagina (stage i-iva), or carcinoma of the vulva (stage i-iva) * life expectancy \> 6 months * mri of the pelvis and/or pet-ct within 4 months prior to entering study exclusion criteria: * uncontrolled intercurrent illness * pacemaker, brain aneurysm clip, inner ear implant, neurostimulator, or metal fragments in the eye

Keywords: brachytherapy gynecological cancer
epidermal growth factor receptor (egfr) t790m mutation testing practices in hong kong

Conditions: Non-small Cell Lung Cancer

Summary: to describe the t790m mutation status of patients with locally advanced/metastatic nsclc who progressed on previous egfr tki treatment in a real-world setting.

this is a multi-center, observational study of patients with locally advanced/metastatic nsclc who progressed on previous egfr tki treatment. eligible patients will be recruited from participating sites in hong kong over a 12 months enrolment period. plasma and urine samples will be collected from enrolled patients. plasma circulating tumor dna (ctdna) and urine ctdna will be analyzed by droplet digital pcr (ddpcr) for detection of t790m mutation and egfr sensitizing mutations. patients who are t790m plasma-negative, regardless of the urine testing results, will be recommended to undergo re-biopsy (defined as tissue sampling or cytology sampling), tissue/cytology t790m testing, and to provide a second plasma sample for a second plasma t790m test (tested by ddpcr). enrolled patients who subsequently receive osimertinib treatment will be followed up as per routine practice at the investigational site. patient data will be collected for 12 months or until death or loss to follow-up, whichever occurs earlier, from the first prescription of osimertinib. all clinical decisions will be at the discretion of the treating physician.

Eligibility criteria:
inclusion criteria * provision of written informed consent * locally advanced (stage iiib) or metastatic (stage iv) nsclc, not amenable to curative surgery or radiotherapy * confirmed egfr sensitizing mutation (exon 19 deletion or exon 21 l858r ) in medical record * progressed on previous egfr tki treatment, based on physician judgement, with or without additional lines of treatment * suggested to undergo t790m mutation testing by treating physician, based on physician judgement exclusion criteria * had been treated with osimertinib or any other 3rd generation t790m inhibitors * enrollment in studies that prohibit participation in this observational study
feasibility and safety of combining anti-malarial with deworming drugs in african children

Conditions: Malaria; Soil Transmitted Helminths; Schistosomiasis; Integrated Control; Seasonal Malaria Chemoprevention; Mass Drug Administration With Anthelminthic Drugs

Summary: malaria remains a major health problem, especially in sub-saharan africa where more than 90% of the disease and deaths occur in children. adding to this high burden among the children is the co-existence of intestinal and genito-urinary worms. prominent among these are soil-transmitted helminths and schistosomiasis. existing control programmes for the worms are operating below the expected level, despite the commitments and support that followed the 2012 london declaration of achieving 75% treatment coverage by 2020. on the other hand, a malaria prevention programme, called seasonal malaria chemoprevention (smc), introduced in the same year 2012 has achieved more than 75% treatment coverage and prevented 75-85% cases of uncomplicated and severe malaria in children. this encouraging development supports the need to explore the strategies involving the integration of worm control with successful platforms such as smc. this would align worm and malaria control with the who road map for neglected tropical diseases (ntd) of ending the neglect to attain sustainable development goals by eradicating diseases of poverty and promoting health and well-being for those at risk. given this context, it is important to develop a treatment approach that combines malaria and helminth control in an integrated framework that will be safe, effective and easy to deliver. this study will, therefore, investigate the feasibility and effectiveness of co-administration of anthelminthic and smc drugs in a high-risk paediatric population living in a malaria-helminth co-endemic setting in senegal, west africa. this study is designed to test the hypothesis that co-administration of smc and anthelminthic drugs will be safe and tolerated among children aged 1-14 years and that the incidence of side effects will not be significant. the objectives of this study are to assess the safety, tolerability, and effects of co-administration of smc and anthelminthic drugs among the children


Eligibility criteria:
inclusion criteria: * male and female children aged 1-14 years; * provision of a written informed consent by the parent/caregiver and a positive assent by children aged ≥ 12 years (in line with legal regulations in senegal); * willingness to provide finger-prick blood samples, urine, and stool samples; * residence in the study area for at least six months exclusion criteria: * acutely ill child at the time of the drug administration; * child whose parents/caregivers decline to provide consent; * a known hiv positive child receiving cotrimoxazole prophylaxis; * a child who has received a dose of any of sulphadoxine-pyrimethamine, amodiaquine, albendazole or praziquantel during the previous six months; * a child with a known allergy to any of sulphadoxine-pyrimethamine, amodiaquine, albendazole or praziquantel.
comparison between the 19 and 22 gauge needles for core tissue procurement during eus-guided procedures

Conditions: Pancreatic Cancer

Summary: the investigators hypothesis is that a 22 gauge needle can yield core tissue, obviating the need to use the 19 gauge needle for core tissue procurement.

inclusion criteria 1. age under 19 years 2. pregnant women will be excluded. this will be confirmed by self-report exclusion criteria 1. age under 19 years 2. pregnant women will be excluded. this will be confirmed by self-report

Eligibility criteria:
inclusion criteria: * all patients who are referred to florida hospital center for interventional endoscopy for a eus fna for core biopsy (19 gauge needle biopsy) who have needle dysfunction (this occurs in about 10% of patients) exclusion criteria: * age under 19 years * pregnant women will be excluded. this will be confirmed by self-report

Keywords: 19 gauge 22 gauge core tissue
neural bases of phantom pain after amputation

Conditions: Phantom Pain

Summary: the amputation of a limb results in chronic pain associated with the lost limb in the majority of patients, which persists over time. despite a large number of studies conducted in an attempt to elucidate the neural basis of phantom pain, these are still not elucidated and current treatments often fail to relieve patients' pain.


Eligibility criteria:
inclusion criteria: * between 18 and 65 years old * for the "amputees with phantom pain" group: patients who have been amputated for more than 2 years and have chronic phantom pain * for the "amputees without phantom pain" group: patients who have been amputated for more than 2 years and do not have chronic phantom pain * for the "healthy participants" group: healthy participants with no neurological history exclusion criteria: * clinically significant pathology (gastrointestinal, renal, hepatic, endocrine, cardiovascular or respiratory) * progressive psychiatric or neurological pathology * on psychotropic medication * pregnant or nursing woman * inadequate level of french language

Keywords: fmri spinal fmri
the effect of omega-3 fatty acid supplementation on intraocular pressure & ocular surface

Conditions: Open Angle Glaucoma; Ocular Hypertension

Summary: this study is designed with the intention to further elucidate the effects of omega-3 fatty acids on intraocular pressure (iop) and signs/symptoms of dry eye. prior studies have shown statistically significant lowering of iop with use of omega-3 fatty acids but have only been performed in animal models. this study will be the first to attempt replication in human models. a limited number of studies have shown an increase in tear production/volume as well as a decrease in the subjective symptoms of dry eye, but more studies are needed to better define these effects. better understanding of the effects of this supplement on intraocular pressure and dry eye will contribute to the expanding knowledge about the pathophysiology of glaucoma/ocular hypertension and dry eye syndrome and potentially lead to further studies about new potential treatment options for these conditions.

the purpose of this research project is to determine the effects of omega-3 fatty acid supplementation on intraocular pressure (iop) as well as the signs and symptoms of dry eye. we hypothesize that dietary omega-3 fatty acid supplementation will be associated with a significant change in intraocular pressure compared to baseline measurements prior to beginning supplementation. we further hypothesize that omega-3 fatty acid supplementation will be associated with a significant increase in tear production and volume as well as a significant change in patients' subjective complaints of dry eye.

Eligibility criteria:
inclusion criteria: * diagnosis of ocular hypertension or open angle glaucoma of mild to moderate severity, with or without previously diagnosed dry eye syndrome, who are currently on monotherapy with a prostaglandin analog. * age 40-89 of either gender, of any race/ethnicity exclusion criteria: * females who are currently pregnant or planning to become pregnant during the study period * age \<40 years old * diagnosis of any other form of glaucoma other than open-angle * patients with known hypersensitivity (i.e., anaphylactic reaction) to omega-3 fatty acids or any of its components * patients with cirrhosis or with known liver disease * patients with diagnosed celiac disease * patients with a hypersensitivity to fish or shellfish * patients with paroxysmal or persistent atrial fibrillation * patients who are currently using medical or recreational marijuana * patients currently on any anticoagulation therapy including warfarin, dabigatran, apixaban, rivaroxaban, clopidogrel, cilostazol, dipyridamole, prasugrel, ticlopidine, ticagrelor * patients currently on lovaza, an omega- 3 fatty acid supplement requiring a prescription * patients with any recent ocular surgery or laser treatment within 3 months
discovering clinical study experiences of patients with pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: taking part in medical trials usually favors a particular demographic group. but there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. this study will admit a wide range of data on the clinical trial experience of pulmonary hypertension patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. it will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future pulmonary hypertension patients.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old * able to comprehend the investigational nature of the protocol and provide informed consent * diagnosis of pulmonary hypertension exclusion criteria: * no diagnosis of pulmonary hypertension confirmed * inability to perform regular electronic reporting * patient does not understand, sign, and return consent form

Keywords: pulmonary hypertension
decision impact trial of kidneyintelx

Conditions: Diabetic Kidney Disease

Summary: the current trial is designed to evaluate how the results of kidneyintelx test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.


Eligibility criteria:
inclusion criteria: * 23 years of age or older. * clinical history of confirmed type 2 diabetes. * evidence of dkd stages 1-3: * baseline egfr of 30-60 ml/min/1.73m2 (confirmed 3 months apart with at least one value within 1 year prior to enrollment) * individuals with egfr ≥60 ml/min/1.73m2 and albuminuria (uacr ≥30mg/g) * all patients will have a hba1c, egfr, urine albumin and urine creatinine, egfr, available from within 12 months of enrollment (to be obtained if not clinically available prior). * the subject must be able to comprehend and sign an approved informed consent form and other applicable study documents. exclusion criteria: * patients with egfr \<30 or ≥ 60 ml/min/1.73m2 without albuminuria. * patients with esrd or on renal recovery treatments at time of enrollment. * patients who are pregnant at the time of enrollment. * patients who are currently hospitalized. * patients who are currently on enbrel.
preoperative radiochemotherapy with hyperthermia for locally advanced rectal cancer

Conditions: Rectal Cancer; Locally Advanced Rectal Cancer; Hyperthermia; Hyperthermic Radiochemotherapy; Hyperthermic Chemoradiotherapy; Deep Regional Hyperthermia

Summary: the current trial is evaluating the impact of deep regional hyperthermia on the pathological complete response rate in locally advanced rectal cancer in the context of preoperative 5fu based radiochemotherapy.


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the rectum (up to 10 cm from the anal verge) * international union against cancer stages ii or iii * ecog ps 0/2 * informed consent exclusion criteria: * congestive heart failure (nyha iii/iv) * history of myocardial infarction within the last 6 months. * av block iii * total hip replacement or major metal pelvic implants * cardiac pacemaker * contraindications for radiochemotherapy * contraindications for surgical tumor resection * previous pelvic radiotherapy or chemotherapy * active chronic inflammatory bowel disease * collagenosis * congenital diseases with increased radiosensitivity * pregnancy or breastfeeding * secondary malignancies other than locally controlled basalioma or in-situ carcinomas infiltration of the anal canal

Keywords: rectal cancer hyperthermia radiochemotherapy chemoradiotherapy deep regional hyperthermia pathologic complete response regression grade locally advanced rectal cancer complete response